Table 2

Clinical data of patients enrolled in this study

Case no.GroupDaysAgeSexDiagnosis
1958MMDS/AML
216–252040MAML
32259FMDS/AML
42357FAML
52534FAML
23±2*48±12†
626–352837MAML
72849FAML
82943FAML
92954MAML
103344MAML
113455MMDS/AML
30±3*47±7†
1236–453627FAML
133655MAML
143659MMDS/AML
153660FMDS/AML
163857FAML
174054MAML
184155FAML
194230MAML
38±3*50±13†
2046–555054MAML
215240MAML
225549FAML
235558FAML
53±2*50±8†
Age-matched poor engraftment group
1Poor2030MAML
22131FAML
32655MAML
43449FAML
25±6*41±13†
Age-matched normocellular group
120FNephrosis
227FLymphadenitis
337MLymphadenitis
452MHyperthyroidism
568MAmyloidosis
675MCOPD
786FLymphadenitis
52±25†
  • Patients were grouped based on the day their clots were sampled. The mean age of each group was not significantly different.

  • *Indicates the average days and SD after CBSCT in each group. Underlines indicate patients whose bone marrow specimens were obtained multiple times.

  • †Indicates the average age and SD in each group.

  • AML, acute myelogenous leukaemia; CBSCT, cord blood stem cell transplantation; COPD, chronic obstructive pulmonary disease; days, sampling days; F, female; M, male; MDS/AML, myelodysplastic syndrome overt AML.